Theravance Biopharma Former Senior Vice President, Corporate Development and Strategy Shehnaaz Suliman's 2018 pay falls 35% to $2.7M
Theravance Biopharma reports 2018 executive compensation
By ExecPay News
Published: March 24, 2020
Theravance Biopharma reported fiscal year 2018 executive compensation information on March 24, 2020.
In 2018, six executives at Theravance Biopharma received on average a compensation package of $1.7M, a 10% decrease compared to previous year.
Average pay of disclosed executives at Theravance Biopharma
Shehnaaz Suliman, Former Senior Vice President, Corporate Development and Strategy, received $2.7M in total, which decreased by 35% compared to 2017. 70% of Suliman's compensation, or $1.8M, was in stock awards. Suliman also received $32K in bonus, $291K in non-equity incentive plan, $484K in salary, as well as $5K in other compensation.
For fiscal year 2018, the median employee pay was $218,626 at Theravance Biopharma. Therefore, the ratio of Shehnaaz Suliman's pay to the median employee pay was 12 to one.
Rick E Winningham, Chief Executive Officer, received a compensation package of $2.5M, which increased by 9% compared to previous year. 38% of the compensation package, or $957K, was in salary.
Brett Haumann, Chief Medical Officer, earned $1.5M in 2018.
Bradford J. Shafer, General Counsel, received $1.1M in 2018, which increases by 11% compared to 2017.
Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer, earned $1.1M in 2018, a 22% increase compared to previous year.
Renee D. Gala, Chief Financial Officer, received $1.1M in 2018, which increases by 13% compared to 2017.
Related executives
Frank Pasqualone
Theravance Biopharma
Senior Vice President and Chief Commercial Operations Officer
Rick Winningham
Theravance Biopharma
Chief Executive Officer
Renee Gala
Theravance Biopharma
Chief Financial Officer
Brett Haumann
Theravance Biopharma
Chief Medical Officer
Bradford Shafer
Theravance Biopharma
General Counsel
Shehnaaz Suliman
Theravance Biopharma
Former Senior Vice President, Corporate Development and Strategy
You may also like
Source: SEC filing on March 24, 2020.